GI
Grifols, S.A.
GIKLY · OTC
$5.71 +2.88% (+$0.16)
1M +1.42%
Market Cap 13.3B €
P/E Ratio 29.43x
Div. Yield 0.83%
ROE 8.43%
Bulios Fair Price
$4.76
16.6% downside
Current Price
$5.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GIKLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
65 /100
Fair P/FCF 17.58x
P/E 29.43x
P/B 2.40x
Growth
64 /100
Stable Book val. growth 4.92%
EPS growth 20.51%
Rev. growth 7.46%
Profitability
64 /100
Moderate Op. margin 16.66%
Gross margin 37.23%
FCF margin 10.19%
Quality
31 /100
Poor ROA 2.25%
ROIC 5.48%
Asset turnover 0.37x
Debt
35 /100
Moderate Int. coverage 2.86x
Debt/Equity 1.54x
Net debt/EBITDA 4.94x
Stability
61 /100
Moderate EPS volatility 132.48%
Beta 1.19x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GIKLY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jose Ignacio Abia Buenache
Employees
25,258
Headquarters
Barcelona
Upcoming events
10 NOV
Earnings
Upcoming earnings report